Wyeth’s Tygacil “Approvable” For CAP, Pushing Back FDA Action Until December
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA seeks more analysis of data on patients with severe illness; Wyeth will submit a "complete response" by June 27.